logo-loader
viewScancell Holdings PLC

Scancell to give six presentations at key cancer conference

It is giving no fewer than six presentations on the company's ImmunoBody and Moditope immunotherapy platforms.

Cancer_561372a0d3523.jpg
Immunotherapy is an emerging and exciting form of science that uses the body’s own immune system to beat diseases such as cancer.

---ADDS SHARE PRICE & BROKER COMMENT---

Scancell Holdings (LON:SCLP) could be accused of hogging the stage at the International Conference on Progress in Vaccination against Cancer, taking place in Germany this week.

For it is giving no fewer than six presentations on the company's ImmunoBody and Moditope immunotherapy platforms.

Immunotherapy is an emerging and exciting form of science that uses the body’s own immune system to battle diseases such as cancer.

The presentations will share with the specialist audience the advances being made with its lead treatment SCIB1 for hard-to-treat cases of melanoma and SCIB2 for lung cancer as well as other developments from the two platforms.

Scancell joint chief-executive, Lindy Durrant, who is also professor of cancer immunotherapy at Nottingham University, said: "Scancell's presentations at this important conference exemplify the growing body of exciting data emerging from both our SCIB1 clinical trial and our ImmunoBody,and Moditope, immunotherapy technology platforms, and provide a solid foundation for building a broad immuno-oncology franchise in the future.

The shares marked time at 23.2p in afternoon trade, valuing the business at £52mln. Panmure Gordon analyst Dr Mike Mitchell reckons the stock is worth 79p.

Of today’s update, he said: “Conference presentations are an important element of the communication of scientific advances and in our view it is notable that six will be delivered at the same event.

“The presentations exemplify the growing body of data that is emerging from Scancell’s technology platforms, reflecting their potential in delivering effective and complimentary immunotherapies to treat a range of cancers.”  

Quick facts: Scancell Holdings PLC

Price: 6.5 GBX

LSE:SCLP
Market: LSE
Market Cap: £30.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital...

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital Conference 

on 03/08/2016

2 min read